CSPC Pharmaceutical Deal History & Licensing Activity
CSPC Pharmaceutical is a large pharma headquartered in China. Over the past three years, CSPC Pharmaceutical has been involved in 7 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
CSPC Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving CSPC Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Kidney disease collaboration program | AstraZeneca | Other | Discovery | collaboration | Jul 2, 2026 |
| Eight obesity/T2D programs plus AI design and LiquidGel technology | AstraZeneca | Other | Preclinical | license | Jan 30, 2026 |
CSPC Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where CSPC Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
CSPC Pharmaceutical Strategic Signals
Key indicators of CSPC Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
CSPC Pharmaceutical Clinical Pipeline
CSPC Pharmaceutical has 50 active clinical trials across 6 development phases.
3
Unknown
1
Not Applicable
9
Phase 1
5
Phase 1/2
11
Phase 2
21
Phase 3
See How Your Asset Matches CSPC Pharmaceutical's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About CSPC Pharmaceutical Licensing & Deal Activity
CSPC Pharmaceutical is a large pharma company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, CSPC Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for CSPC Pharmaceutical include Solid Tumors (19 deals and trials), Metabolic (15 deals and trials), Oncology (3 deals and trials), and CNS Disorders (3 deals and trials). In terms of modality, CSPC Pharmaceutical has shown particular interest in other, adc, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for CSPC Pharmaceutical and 700+ other biopharma companies. Use our Solidus to benchmark your asset against CSPC Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.